Abstract Number: 0011 • ACR Convergence 2020
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…Abstract Number: 0299 • ACR Convergence 2020
The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a clinically heterogenous autoimmune disease characterized by autoantibody- and complement-mediated inflammatory damage to multiple organ systems. We previously showed…Abstract Number: 0558 • ACR Convergence 2020
Statin Use Pattern in Patients with Inflammatory Joint Disease in a Single Site VA Medical Center
Background/Purpose: Patients with inflammatory joint disease, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) carry increased risk of cardiovascular disease (CVD). Mechanisms…Abstract Number: 0843 • ACR Convergence 2020
Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
Background/Purpose: HRES-1/Rab4 or Rab4A, a GTPase responsible for mitochondrial oxidative stress1 and activation of the mechanistic target of rapamycin2, is overexpressed in T cells of…Abstract Number: 1048 • ACR Convergence 2020
Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
Background/Purpose: In the randomized placebo-controlled INBUILD trial in patients with chronic fibrosing ILDs with a progressive phenotype, nintedanib reduced the rate of decline in forced…Abstract Number: 1287 • ACR Convergence 2020
Prevalence of Morbidity Prior to Diagnosis of Incident Systemic Lupus Erythematosus in the Danish Population
Background/Purpose: Patients with SLE experience a high burden of various comorbidities at disease onset and during disease progression. Studies of excess morbidity prior to SLE…Abstract Number: 1450 • ACR Convergence 2020
Integrative Analysis of DNA Methylation and Gene Expression in Monocytes from Primary Antiphospholipid Syndrome Patients Identifies a Gene Expression Signature Associated with Their Atherothrombotic Phenotype
Background/Purpose: 1. To develop integrated analyses of the genome-wide DNA methylation and gene expression profiles in monocytes from APS patients and assess their involvement in…Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…Abstract Number: 2046 • ACR Convergence 2020
Alterations in Circulating CD4+ T Cell Phenotypes in CCP+ Early RA and CCP+ At-risk Individuals by Mass Cytometry
Background/Purpose: The cyclic citrullinated peptide (CCP) autoantibody is a highly specific and predictive marker for the clinical diagnosis of RA. Elevation in CCP titers can be…Abstract Number: 0014 • ACR Convergence 2020
Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have an increased risk for infection related to immunosuppression secondary to their disease, treatment and comorbidities. Nonetheless recent…Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…Abstract Number: 0559 • ACR Convergence 2020
Low Frequency of ANA/DFS70 Pattern Positive Result in a Large Cohort of Autoimmune/autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated in a Single Hospital from Colombia
Background/Purpose: Autoimmune systemic rheumatic disease (SARD) diagnostic approach is complex and recently there are some diagnostic tools to rule-out autoimmune disease diagnoses. ANAS/DFS70 antibodies have…Abstract Number: 0854 • ACR Convergence 2020
Mortality and Adverse Events of Special Interest in Adult Patients with Systemic Lupus Erythematosus Receiving Intravenous Belimumab: A Post Hoc Descriptive Summary of Serious Psychiatric Events
Background/Purpose: Intravenous (IV) belimumab (BEL) is approved in patients ≥5 years of age with active systemic lupus erythematosus (SLE). Results of the BASE study (the…Abstract Number: 1049 • ACR Convergence 2020
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…Abstract Number: 1296 • ACR Convergence 2020
Associations of Metabolic Syndrome and Adipokines in SLE
Background/Purpose: Metabolic syndrome (MetS) is a chronic pro-inflammatory and pro-thrombotic state associated with increased atherosclerosis, cardiovascular events and type 2 diabetes. It is diagnosed in…
- « Previous Page
- 1
- …
- 61
- 62
- 63
- 64
- 65
- …
- 80
- Next Page »